Cabotegravir Plus Rilpivirine: First Approval

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

(2020) Chloe Orkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results

(2019) David Margolis et al.   Open Forum Infectious Diseases

In vitro antiviral activity of cabotegravir against HIV-2

(2018) Robert A. Smith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

(2018) Steven J. Smith et al.   Retrovirology

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

(2013) W. Spreen et al.   HIV CLINICAL TRIALS